Full history for every metric is available with a Kvantra account
Nextgen Biomed Ltd (NXGN.TA)
Key financial summary
Financials in ILS| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ILS m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | ILS m | -5 | -9 | |||||
| Net profit | ILS m | -1 | -1 | -3 | -9 | -14 | -5 | -13 |
| EPS reported | ILS | -0.58 | -1.17 | |||||
| Operating cashflow per share | ILS | -0.24 | -0.14 | |||||
| Capex per share | ILS | 0.01 | 0.00 | |||||
| FCF per share | ILS | -0.26 | -0.14 | |||||
| Free cash flow | ILS m | -2 | -3 | |||||
| Net debt | ILS m | -0 | 2 | |||||
| Book value equity | ILS m | -2 | -8 | |||||
| Book value per share | ILS | -0.28 | -0.72 | |||||
| Number of shares | m | 8.42 | 11.54 | |||||
| DPS (TTM paid) | ILS | 0.00 | 0.00 |
Financial summary
Financials in ILS| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -2.19 | -0.62 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -2.37 | -1.84 | |||||
| EV/EBITDA LTM | x | -1.11 | -0.54 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -95.27% | -176.11% | |||||
| FCF Yield | % | -42.14% | -54.31% | |||||
| Quality | ||||||||
| ROE | % | 208.97% | 115.56% | |||||
| ROIC | % | 217.34% | 82.11% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -9.75 | -0.98 | |||||
| Net Debt/EBITDA | x | -0.04 | -0.23 | |||||
| EBIT/Net interest | x | -975.00 | -18.86 | |||||
| Net debt/market cap | % | -1.27% | 48.52% | |||||
| Net debt/Equity | x | 0.03 | -0.30 | |||||
| Gross debt/equity | x | -0.09 | -0.34 | |||||
Company overview
Nextgen Biomed Ltd focuses on developing external dermatological treatments for psoriasis. The company, which was established in 1990, originally operated under the name Sela Group.Com Ltd. before rebranding as Nextgen Biomed Ltd in February 2010. Its operations are headquartered in Tel Aviv, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nextgen Biomed Ltd (NXGN.TA)
Nextgen Biomed Ltd focuses on developing external dermatological treatments for psoriasis. The company, which was established in 1990, originally operated under the name Sela Group.Com Ltd. before rebranding as Nextgen Biomed Ltd in February 2010. Its operations are headquartered in Tel Aviv, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free